Karyopharm Therapeutics
KPTI
108 hedge funds and large institutions have $300M invested in Karyopharm Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 26 closing their positions.
214% more call options, than puts
Call options by funds: $4.08M | Put options by funds: $1.3M
100% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 21
0.03% less ownership
Funds ownership: 5.65% → 5.61% (-0.03%)
6% less funds holding
Funds holding: 115 → 108 (-7)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
38% less capital invested
Capital invested by funds: $482M → $300M (-$182M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$16.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$11.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.54M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$4.26M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$13M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.5M |
| 4 |
DM
Deerfield Management
New York
|
-$4.45M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.52M |
KPTI Hedge Fund Activity: Q1 2019 in Review
108 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2019, worth a combined $300M — down 38% from $482M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KPTI and 19 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 42 added.
The largest buyer was Millennium Management, adding an estimated $16.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.4M sold.
- 108 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2019, down from 115 in Q4 2018.
- Funds reported $300M of Karyopharm Therapeutics stock for Q1 2019, down 38% quarter-over-quarter.
- 19 funds opened new Karyopharm Therapeutics positions in Q1 2019 and 26 closed out, a net change of -7 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $16.8M added.
- The largest Karyopharm Therapeutics seller in Q1 2019 was Point72 Asset Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q1 2019.